VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Mimedx Group Executive Compensation (FY25)

MDXG · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Joseph Capper
Median of the other named officers
$2,119,729
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 10, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Mimedx Group brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 16, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Mimedx Group brief$500Get the executive brief
Velarion Intel, one year, every company
246 figures on this page: 239 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Joseph Capper: $1,389,859 → $7,182,208
Say-on-pay support: 93.2% → 95.6% (2.4 points higher)
CEO pay ratio: 14:1 → 70:1

Frequently asked questions

Answers drawn from the data on this page.
Who is Mimedx Group's chief executive and what were they paid?
Joseph Capper, Chief Executive Officer, received $7,182,208 in total compensation for fiscal 2025. Compared with the $1,389,859 reported for fiscal 2024, Capper's total was up.
What was Mimedx Group's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 95.6% of votes cast for or against in favor at the meeting held June 10, 2026.
Which companies are in Mimedx Group's peer group?
The disclosed peer group includes ADMA Biologics, Inc., Alphatec Holdings, Inc., AngioDynamics, Inc., Anika Therapeutics and Artivion, Inc., among others.
What is Mimedx Group's chief executive pay ratio?
The company reported a chief executive pay ratio of 70:1 for fiscal 2025, against median employee compensation of $103,278.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Carlson
EVP - Finance and Chief Financial Officer
◇—◇—◇—◇◇
William Hulse IV
General Counsel and Chief Administrative Officer
◇———◇—◇— not reconciled
Robert Stein
President, Regenerative Medicine & Biologics Innovation
◇—◇—◇—◇◇
Rohit Kashyap
Former President, Wound Care & Surgical
Departed during or after this year
◇—◇—◇—◇◇
K. Todd Newton
Interim Chief Executive Officer
Served on an interim basis
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Capper
Chief Executive Officer
◇—◇◇◇—◇◇
Ricci Whitlow
EVP & Chief Operating Officer
◇◇◇—◇—◇◇
Doug Rice
Chief Financial Officer
◇—◇◇◇—◇◇
William Hulse IV
General Counsel and Chief Administrative Officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kimberly Maersk-Moller
Chief Commercial Officer
◇—◇◇◇—◇◇
William Hulse IV
General Counsel and Chief Administrative Officer
◇—◇◇◇—◇◇
Doug Rice
Chief Financial Officer
◇—◇◇◇—◇◇
Ricci Whitlow
EVP & Chief Operating Officer
◇—◇◇◇—◇◇
Joseph Capper
Chief Executive Officer
◇———◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Capper
Chief Executive Officer
◇—◇◇◇—◇◇
William Hulse IV
General Counsel and Chief Administrative Officer
◇—◇◇◇—◇◇
William Hulse
General Counsel and Chief Administrative Officer
◇—◇◇◇—◇◇
Doug Rice
Chief Financial Officer
◇—◇◇◇—◇◇
Ricci Whitlow
Executive Vice President and Chief Operating Officer
◇—◇◇◇—◇◇
Kimberly Maersk-Moller
Chief Commercial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Doug RicePSU◇◇◇—◇—◇
Joseph H. CapperPSU◇—— withheld◇◇—◇
Joseph H. CapperPSU◇◇◇—◇—◇
Joseph H. CapperRSU◇——◇——◇
Kimberly Maersk-MollerPSU◇◇◇—◇—◇
Kimberly Maersk-MollerOPTION◇——◇—◇◇
Kimberly Maersk-MollerRSU◇——◇——◇
Ricci S. WhitlowPSU◇◇◇—◇—◇
Ricci S. WhitlowOPTION◇——◇—◇◇
Ricci S. WhitlowRSU◇——◇——◇
William F. Hulse IVPSU◇◇◇—◇—◇
William F. Hulse IVOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Joseph CapperOption◇—◇1/30/2030
Option◇—◇3/3/2032
William HulseOption◇—◇3/1/2031
Option◇—◇3/3/2032
Ricci WhitlowOption◇—◇3/1/2031
Option◇—◇3/3/2032
Doug RiceOption◇—◇3/1/2031
Option◇—◇7/5/2030
Option◇—◇3/3/2032
RSU◇◇——
Kimberly Maersk-MollerOption◇—◇3/3/2032
Option◇—◇3/1/2031
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
M. Kathleen Behrens
Board chair
◇◇————◇
James L. Bierman
◇◇————◇
K. Todd Newton
◇◇————◇
Cato T. Laurencin
◇◇————◇
William A. Hawkins
◇◇————◇
Dorothy E. Puhy
◇◇————◇
Tiffany P. Olson
◇◇————◇
Martin P. Sutter and Joseph H. Capper served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Restricted Stock.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ADMA Biologics, Inc. ADMA
  • Alphatec Holdings, Inc. ATEC
  • AngioDynamics, Inc. ANGO
  • Anika Therapeutics ANIK
  • Artivion, Inc. AORT
  • AVITA Medical, Inc. XTNT
  • Axonics, Inc. AXNX
  • Bioventus Inc. BVS
  • CareDx, Inc. CDNA
  • Integra Life Sciences Holdings Corporation symbol not shown
  • OraSure Technologies, Inc. OSUR
  • Organogenesis Holdings Inc. ORGO
  • Orthofix Medical Inc OFIX
  • Outset Medical, Inc. OM
  • Standard BioTools Inc. LAB
  • Tactile Systems Technology, Inc. TCMD
  • Veracyte, Inc. VCYT
  • Vericel Corporation VCEL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 10, 2026=◇◇◇
2024June 18, 2025=◇◇◇
2023June 5, 2024=◇◇◇
2022June 13, 2023=◇◇◇
2021June 7, 2022=◇◇◇
2020May 27, 2021=◇◇◇
2015May 18, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Joseph Capper (Chief Executive Officer), FY2025 total compensation $7,182,208 (base salary $768,173) [exec_comp, SEC accession 0001376339-26-000033, filed 2026-04-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Mimedx Group files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Mimedx Group disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Mimedx Group sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Mimedx Group's disclosed peer group is defensible, who names Mimedx Group back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
246 figures on this page: 239 cited to the filing that reported them, 7 calculated from figures it prints.
239 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001376339-26-000052
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001376339-26-000033
    CEO PAY RATIO · DIRECTOR COMPENSATION · Grants of Plan-Based Awards For 2025 · Grants of Plan-Based Awards for 2025 · and 1 more section
  3. 0001376339-25-000059
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001376339-24-000055
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001376339-23-000033
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001140361-23-024514
    Summary Compensation Table (2022, 2021 and 2020)
  7. 0001193125-22-173037
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001376339-21-000083
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001376339-16-000175
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Mimedx Group executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/MDXG (accessed 2026).
Short form: data: Velarion

The Mimedx Group brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Mimedx Group and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Mimedx Group discloses

The companies named in MDXG's own disclosed peer group.

ADMA Biologics, Inc.Alphatec Holdings, Inc.AngioDynamics, Inc.Anika TherapeuticsArtivion, Inc.AVITA Medical, Inc.Bioventus Inc.CareDx, Inc.OraSure Technologies, Inc.Organogenesis Holdings Inc.Orthofix Medical IncOutset Medical, Inc.Standard BioTools Inc.Tactile Systems Technology, Inc.Veracyte, Inc.Vericel Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy